{"id":457527,"date":"2019-12-18T06:40:02","date_gmt":"2019-12-18T06:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=457527"},"modified":"2019-12-18T06:40:02","modified_gmt":"2019-12-18T06:40:02","slug":"antibody-drug-conjugate-market-therapeutic-analysis-by-types-technology-and-global-industry-trends-mrfr-business-outlook-2019-to-2023","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/antibody-drug-conjugate-market-therapeutic-analysis-by-types-technology-and-global-industry-trends-mrfr-business-outlook-2019-to-2023_457527.html","title":{"rendered":"Antibody Drug Conjugate Market Therapeutic Analysis By Types, Technology and Global Industry Trends | MRFR Business Outlook 2019 To 2023"},"content":{"rendered":"
\n
ANTIBODY DRUG CONJUGATE MARKET<\/div>\n<\/div>\n
Antibody Drug Conjugate Market Research By Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies) – Global Industry Forecast 2023\n<\/div>\n

ANTIBODY DRUG CONJUGATE MARKET OVERVIEW<\/strong><\/p>\n

Antibody drug conjugates (ADCs) are a new class of biopharmaceutical drug containing an antibody with to a biologically active drug. They are designed to eliminate the tumor after being released in the bloodstream to target cancerous cells. The global antibody drug conjugate market report by Market Research Future (MRFR) contains in detail the effects of ADCs as well as the large potential in medical applications.<\/p>\n

The global antibody drug conjugate market share is expected to grow at a 19% CAGR from 2017 to 2023 (forecast period). This can be attributed to successful clinical trials by prominent companies as well as development of other drugs in the pipeline can augur favorably for the segment growth.<\/p>\n

Avail a FREE Sample: https:\/\/www.marketresearchfuture.com\/sample_request\/1113<\/a> <\/strong><\/p>\n

Emergence of targeted therapies and high prevalence of various cancers are other drivers of the market. Increased investment by drug manufacturers and collaboration between biotechnology and biopharmaceutical companies can bolster the market growth.<\/p>\n

Antibody Drug Conjugates Market<\/strong> Segmentation Analysis<\/strong><\/p>\n

The antibody drug conjugate market is segmented by type, product, technology, application, and end-user.<\/p>\n

By type:               drug\/toxin, monoclonal antibodies, and others.<\/p>\n

By product:         Kadcyla, Adcertis, and others.<\/p>\n

By technology:  Immunomedics technology, ImmunoGen technology, Seattle Genetics technology, and others.<\/p>\n

By application, breast cancer, kidney cancer, lymphoma, lung cancer, multiple myeloma, pancreas cancer, prostate cancer, ovary cancer, glioblastoma, leukemia, colon cancer, solid tumors, skin cancer, and others. Breast cancer can be the largest segment during the forecast period due to high incidence of such cancers.<\/p>\n

By treatment:    targeted therapy, hormone therapy, radiation therapy, chemotherapy, surgery, and others. Chemotherapy and targeted therapy are segments deemed to gain maximum revenue for the antibody drug conjugate market in the coming years.<\/p>\n

By end-user:      hospitals, biopharmaceutical companies, academic research institutes, specialized cancer centers, biotechnology companies, and others.<\/p>\n

Antibody Drug Conjugates Market<\/strong> Competitive Outlook<\/strong><\/p>\n

Here are some of the major players in the antibody drug conjugate market Listed below-<\/p>\n

Synthon<\/p>\n

Seattle Genetics<\/p>\n

Mersana Therapeutics<\/p>\n

Concortis Biotherapeutics<\/p>\n

Agensys Inc.<\/p>\n

Pfizer Inc.<\/p>\n

AbbVie Inc.<\/p>\n

ImmunoGen Inc.<\/p>\n

Millennium Pharmaceuticals<\/p>\n

Roche Holding AG<\/p>\n

Antikor<\/p>\n

Immunomedics<\/p>\n

Heidelberg Pharma<\/p>\n

Genentech<\/p>\n

Oxford BioTherapeutics<\/p>\n

Astellas Pharma\/Agensys<\/p>\n

Progenics Pharmaceuticals<\/p>\n

Bayer HealthCare<\/p>\n

Celldex Therapeutics<\/p>\n

and others<\/p>\n

Avail an Amazing Discount: https:\/\/www.marketresearchfuture.com\/check-discount\/1113<\/a> <\/strong><\/p>\n

Collaborations and partnerships are at an all-time high as evident by the plans of these companies to gain a wider consumer base. Collaborations would assist companies to gain license of drugs and mass produce them effectively in countries with lax regulations and taxes.<\/p>\n

 <\/p>\n

Global Antibody Drug Conjugates Market Regional Analysis<\/strong><\/p>\n

Asia Pacific (APAC), the Americas, the Middle East & Africa (MEA), and Europe are regions covered in the global antibody drug conjugate market report.<\/p>\n

The Americas is predicted to be the leading region in the market followed by Europe. The region is expected to experience a massive windfall due to implementation of nanotechnology for hosting ADCs, advances in manufacturing processes, and technological breakthroughs. Presence of prominent drug manufacturers combined with approval of drugs are likely to augment the global market revenue manifold.<\/p>\n

The APAC region is expected to be one of the biggest regions in the coming years due to heavy investments by biopharmaceutical companies. Furthermore, outsourcing of drug contracts to India and China due to cost-effective labor and skilled personnel can influence the regional antibody drug conjugate market growth.<\/p>\n

Complete Premium Research Details: https:\/\/www.marketresearchfuture.com\/reports\/antibody-drug-conjugate-market-1113<\/a> <\/strong><\/p>\n

TABLE OF CONTENT<\/strong><\/p>\n

Chapter 1. Report Prologue<\/p>\n

Chapter 2. Market Introduction<\/p>\n

Chapter 3. Research Methodology<\/p>\n

Chapter 4. Market Dynamics<\/p>\n

Chapter 5. Market Factor Analysis<\/p>\n

Chapter 6. Global Antibody Drug Conjugate Market, By Type<\/p>\n

Chapter 7. Global Antibody Drug Conjugate Market, By Application<\/p>\n

Chapter 8. Global Antibody Drug Conjugate Market, By Product<\/p>\n

Chapter 9. Global Antibody Drug Conjugate Market, By Technology<\/p>\n

Chapter 10. Global Antibody Drug Conjugate Market, By End-User<\/p>\n

Chapter 12. Global Antibody Drug Conjugate Market, By Region<\/p>\n

Chapter 13. Company Landscape<\/p>\n

Chapter 14. Company Profiles<\/p>\n

Chapter 15. MRFR Conclusion<\/p>\n

Chapter 16. Appendix<\/p>\n

LIST OF TABLES<\/p>\n

LIST OF FIGURES<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Market Research Future<\/a>
Contact Person:<\/strong> Abhishek Sawant
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 646 845 9312
Address:<\/strong>Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> https:\/\/www.marketresearchfuture.com\/reports\/antibody-drug-conjugate-market-1113<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

ANTIBODY DRUG CONJUGATE MARKET Antibody Drug Conjugate Market Research By Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies) – Global Industry Forecast 2023 ANTIBODY DRUG CONJUGATE MARKET OVERVIEW Antibody drug … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,410,417,406],"tags":[],"class_list":["post-457527","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Manufacturing-Industry","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/457527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=457527"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/457527\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=457527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=457527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=457527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}